OnDosis first patent issued by the United States Patent and Trademark Office
..............................................................
GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag:
..............................................................
OnDosis have announced that the company´s first patent was issued by the United States Patent and Trademark Office (USPTO) on April 11th 2023, with the patent number 11622914.
The issued patent covers the Dosage Manager device platform developed by OnDosis for dosing of oral solid medicines in the form of pellets. The issued patent is the first relating to OnDosis innovative device and its core design and functionality, and the company expects further patents to follow in due course from the company’s extensive patent portfolio.
“We are very pleased with this first issued patent for our invention, the Dosage Manager, which is now at final stage of development and expected to undergo a regulatory approval process in the US during 2024 as a part of a drug/device combination aimed to improve treatment of patients with ADHD”, says Martin Olovsson, CEO at OnDosis, and continues “the US is the most important market for us at this stage since this is where we target our first launch, and due to its size and its openness to innovation. We are very excited by the fact that our first issued patent is in the US.”
The OnDosis Dosage Manager is developed as a device platform technology which can be adopted and scaled across a multitude of disease areas. OnDosis collaborates with leading pharmaceutical companies to bring drug/device combination products to market for the benefits of patients, the healthcare system and society.
The benefit of a Dosage Manager drug/device combination is the ability to deliver flexible, precise, and individual dosing of medicines where dose titration and adjustments are essential to reach desired outcomes. Other benefits are the ability to, through connection with digital services, engage patients into their care and to provide better insights for healthcare professionals on the relation between dosage and outcomes. In addition, the Dosage Manager promotes safe use through features ensuring that the right dose is taken by the right patient, at the right time. Medicines delivered in the form of pellets are easier to swallow, something that can be valuable when delivering medicines for children.
OnDosis have several development projects ongoing in collaboration with Tiefenbacher Group (Hamburg, Germany) under the OYSTA®brand, and with other undisclosed biopharmaceutical companies. The first project in collaboration with Tiefenbacher is expected to reach the US market in 2025, aiming to improve treatment for patients with ADHD.
Besides ADHD, other CNS related diseases as well as cardiovascular, oncology, orphan and pediatric indications are in focus for future developments.
About OnDosis
A MedTech company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage - individualized, intuitive, and intelligent - in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. Pls visit:www.ondosis.com.
For more information, please contact:
Martin Olovsson
CEO, OnDosis
Tel: +46 76 772 85 01